DA Davidson analyst Linda Bolton Weiser raised the firm’s price target on Clorox (CLX) to $171 from $153 and keeps a Neutral rating on the shares after its Q1 earnings beat. The company saw a strong 31% organic sales growth against the cyberattack-impacted quarter last year while retailers also took some flu season shipments early, shifting sales from Q2, the analyst tells investors in a research note. The firm adds however that abnormal cyberattack comparisons go away in the second half of FY25, so organic sales growth is expected to be in the normalized range of 3%-5%.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLX:
- Clorox price target raised to $171 from $153 at DA Davidson
- Clorox price target raised to $139 from $137 at Barclays
- Clorox CEO: We entered the fiscal year with strong momentum
- Clorox Company Reports Strong Q1 2025 Financial Results
- Closing Bell Movers: Microsoft, Meta both down about 3% despite earnings beats